Clinical efficacy of neoadjuvant chemoradiotherapy followed by surgery for locally advanced esophageal squamous cell carcinoma
10.3760/cma.j.issn.1004-4221.2015.03.002
- VernacularTitle:局部晚期食管鳞癌新辅助放化疗联合手术治疗的临床疗效分析
- Author:
Shiliang LIU
;
Mian XI
;
Yadi YANG
;
Lei ZHAO
;
Jianhua FU
;
Mengzhong LIU
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms/neoadjuvant chemoradiotherapy;
Clinical complete response;
Pathologic complete response;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2015;24(3):232-236
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy of neoadjuvant chemoradiotherapy (CRT) followed by surgery for locally advanced esophageal squamous cell carcinoma (ESCC),and to investigate the correlation between a clinical complete response (cCR) and a pathologic complete response (pCR).Methods One hundred and fifty-eight patients with locally advanced thoracic ESCC from 2001 to 2013 were retrospectively analyzed.All patients received concurrent chemoradiotherapy followed by surgery.Platinumbased chemotherapy regimens were adopted in chemotherapy and a prescribed dose of 40 Gy in 20 fractions,5 fractions per week,was used in radiotherapy.The overall survival (OS) and disease-free survival (DFS) rates were calculated using the Kaplan-Meier method,and pairwise comparisons and univariate prognostic analyses were performed using the log-rank test.Multivariable prognostic analyses were performed using the Cox regression model.Results The pCR rate was 41.1% in all patients.After the treatment with neoadjuvant CRT,32(72.7%) out of 44 patients with a cCR had a pCR,but only 33(28.9%) out of 114 patients with a non-cCR had a pCR (P =0.000).The sensitivity,specificity,positive predictive value,and negative predictive value of a cCR in predicting a pCR were 49.2%,87.1%,72.7%,and 71.1%,respectively.The 3-year sample size was 91.The 3-year OS and DFS rates in all patients were 53.9% and 48.6%,respectively.Patients with a cCR had significantly higher 3-year OS and DFS rates than those with a non-cCR (P =0.012;P =0.026),while patients with a pCR had significantly higher 3-year OS and DFS rates than those with a non-pCR (P =0.000;P =0.000).The multivariate analyses demonstrated that the pathologic response after CRT and chemotherapy regimen were the influencing factors for OS.The most common grade ≥3 acute adverse reaction was leucopenia (34.2%).Conclusions With a high pCR rate and tolerable adverse reactions,neoadjuvant CRT followed by surgery is a safe and effective option for locally advanced ESCC.The cCR rate after CRT is closely correlated with the pCR and OS rates.